By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merz Pharma GmbH & Co. KGaA 

Eckenheimer Landstra├če 100-104

Frankfurt am Main    D-60318  Germany
Phone: 49-69-15-03-1 Fax: 49-0-69-15-03-200




Forest  Licensing agreement for the development and marketing in the U.S. of memantine for the treatment of Alzheimer's Disease and neuropathic pain. Licensing agreement for neramexane, a patented novel NMDA receptor antagonist that is being investigated for a broad range of possible indications related central nervous system disorders.

Company News
Merz Pharma GmbH & Co. KGaA Announces New Investment In Cytrellis Biosystems 4/27/2016 10:43:39 AM
Forest Laboratories, Inc. (FRX) Files Lawsuit Against Several Companies For Infringement Of NAMENDA XR ® Patents 2/3/2014 7:17:47 AM
Forest Laboratories, Inc. (FRX), Merz Pharma GmbH & Co. KGaA Settle Patent Dispute Over Namenda 7/23/2010 7:16:14 AM
Neurobiological Technologies, Inc. (NTII) Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine 2/3/2009 8:26:16 AM
Forest Laboratories, Inc. (FRX) and Merz Pharma GmbH & Co. KGaA File Additional Lawsuit Against Several Companies for Patent Infringement 1/25/2008 11:20:45 AM
Forest Laboratories, Inc. (FRX) and Merz GmbH & Co. KGaA File Lawsuits Against Several Companies for Patent Infringement 1/11/2008 7:54:30 AM
Bernhard Scheuble Appointed As CEO Of The MERZ Group 9/27/2006 1:51:01 PM
Neurobiological Technologies, Inc. (NTII) Receives $1.1 Million Royalty Payment Related To Memantine10/19/2005 5:10:41 PM
Forest Laboratories, Inc. (FRX) Announces That Neramexane Did Not Demonstrate Statistical Significance In Recently Completed Phase III Trial In Patients With Moderate To Severe Alzheimer's Disease10/19/2005 5:10:29 PM
Merz GmbH & Co. KGaA Release: Memantine Captures US Market 10/19/2005 5:10:11 PM